Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Akero Therapeutics, Inc. (AKRO)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 61,281,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Akero Therapeutics is a clinical-stage company developing treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Co.'s primary product candidate, efruxifermin, is an analog of fibroblast growth factor 21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 200,000 680,000 1,200,000
Total Buy Value $0 $3,677,505 $17,491,214 $32,931,214
Total People Bought 0 1 1 1
Total Buy Transactions 0 3 7 9
Total Shares Sold 110,332 146,617 519,059 3,046,073
Total Sell Value $3,553,208 $4,303,932 $22,222,916 $129,158,693
Total People Sold 5 5 7 9
Total Sell Transactions 9 18 44 86
End Date 2024-02-29 2023-11-28 2023-05-30 2022-05-30

   
Records found: 303
  Page 12 of 13  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Versant Venture Capital Vi, L.p. 10% Owner   –       –       •   2019-12-27 4 AS $22.58 $750,920 D/D (33,256) 4,012,711     -
   Versant Venture Capital Vi, L.p. 10% Owner   –       –       •   2019-12-26 4 AS $22.48 $530,528 D/D (23,600) 4,045,967     -
   Versant Venture Capital Vi, L.p. 10% Owner   –       –       •   2019-12-24 4 AS $21.70 $34,829 D/D (1,605) 4,069,567     -
   Versant Venture Capital Vi, L.p. 10% Owner   –       –       •   2019-12-23 4 AS $21.56 $117,135 D/D (5,433) 4,071,172     -
   Versant Venture Capital Vi, L.p. 10% Owner   –       –       •   2019-12-20 4 AS $19.80 $367,924 D/D (18,582) 4,076,605     -
   Versant Venture Capital Vi, L.p. 10% Owner   –       –       •   2019-12-18 4 AS $19.50 $39,390 D/D (2,020) 4,095,187     -
   Versant Venture Capital Vi, L.p. 10% Owner   –       –       •   2019-12-17 4 AS $19.58 $149,807 D/D (7,651) 4,097,207     -
   Atlas Venture Opportunity Fund I, L.p. 10% Owner   –       –       •   2019-12-17 4 AS $0.00 $0 I/I (570,974) 454,589     -
   Atp Iii Gp, Ltd. 10% Owner   –       –       •   2019-06-24 4 B $16.00 $14,400,000 D/D 900,000 5,415,203 2.45     -
   Atp Iii Gp, Ltd. 10% Owner   –       –       •   2019-06-24 4 A $0.00 $0 D/D 4,515,203 4,515,203     -
   Atlas Venture Opportunity Fund I, L.p. 10% Owner   –       –       •   2019-06-24 4 B $16.00 $4,320,000 I/I 270,000 505,099 1.5     -
   Atlas Venture Opportunity Fund I, L.p. 10% Owner   –       –       •   2019-06-24 4 A $0.00 $0 I/I 3,704,858 235,099     -
   Versant Venture Capital Vi, L.p. 10% Owner   –       –       •   2019-06-24 4 B $16.00 $6,400,000 D/D 400,000 4,104,858 2.45     -
   Versant Venture Capital Vi, L.p. 10% Owner   –       –       •   2019-06-24 4 A $0.00 $0 D/D 3,704,858 3,704,858     -
   Harrison Seth Loring Director   –       •       •   2019-06-24 4 B $16.00 $14,400,000 I/I 900,000 5,415,203 2.25     -
   Harrison Seth Loring Director   –       •       •   2019-06-24 4 A $0.00 $0 I/I 4,515,203 4,515,203     -
   Bitterman Kevin Director   –       •      –    2019-06-24 4 B $16.00 $4,320,000 I/I 270,000 505,099 2.1     -
   Bitterman Kevin Director   –       •      –    2019-06-24 4 A $0.00 $0 I/I 3,704,858 235,099     -
   Royston Aaron Director   –       •      –    2019-06-24 4 A $0.00 $0 I/I 3,704,858 3,954,858     -
   Royston Aaron Director   –       •      –    2019-06-24 4 B $16.00 $4,000,000 I/I 250,000 250,000 2.1     -
   Goodman Corey S 10% Owner   –       –       •   2019-06-24 4 A $0.00 $0 I/I 3,704,858 3,954,858     -
   Goodman Corey S 10% Owner   –       –       •   2019-06-24 4 B $16.00 $4,000,000 I/I 250,000 250,000 1.5     -
   Green Jeremy 10% Owner   –       –       •   2019-06-24 4 A $0.00 $0 I/I 743,802 743,802     -
   Rolph Timothy Chief Scientific OfficerOffice   •       –      –    2019-06-19 3 IO $0.00 $0 D/D 0 192,909     -
   Cheng Andrew President and CEOOfficer   •       •      –    2019-06-19 3 IO $0.00 $0 D/D 0 325,289     -

  303 Records found
  Previous  10  11  12  13   
  Page 12 of 13
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed